Mochida Pharmaceutical（MFY）株式概要持田製薬株式会社は日本で医薬品とヘルスケア製品を製造・販売している。 詳細MFY ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績4/6財務の健全性4/6配当金3/6報酬株価収益率（ 14 x） German市場（ 17.3 x）を下回っています。過去1年間で収益は39%増加しました リスク分析過去5年間で収益は年間11.6%減少しました。 2.72%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見るMFY Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair Value€Current Price€16.3025.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0121b2016201920222025202620282031Revenue JP¥121.4bEarnings JP¥8.2bAdvancedSet Fair ValueView all narrativesMochida Pharmaceutical Co., Ltd. 競合他社Dermapharm HoldingSymbol: XTRA:DMPMarket cap: €2.0bMerck KGaASymbol: XTRA:MRKMarket cap: €60.3bTempo Scan PacificSymbol: IDX:TSPCMarket cap: Rp12.2tSCHOTT Pharma KGaASymbol: XTRA:1SXPMarket cap: €3.1b価格と性能株価の高値、安値、推移の概要Mochida Pharmaceutical過去の株価現在の株価JP¥16.3052週高値JP¥21.8052週安値JP¥16.20ベータ0.0921ヶ月の変化-2.40%3ヶ月変化-7.91%1年変化-5.78%3年間の変化-20.87%5年間の変化-40.51%IPOからの変化-10.07%最新ニュースお知らせ • Jun 03Mochida Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 03, 2026Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 03, 2026Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥223 (vs JP¥160 in FY 2025)Full year 2026 results: EPS: JP¥223 (up from JP¥160 in FY 2025). Revenue: JP¥117.0b (up 11% from FY 2025). Net income: JP¥7.90b (up 39% from FY 2025). Profit margin: 6.8% (up from 5.4% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Board Change • May 20Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Outside Director Sanae Tanaka was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • May 15Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026.お知らせ • May 09Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026お知らせ • Mar 30Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces an Equity Buyback for 530,000 shares, representing 1.5% for ¥2,000 million.Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces a share repurchase program. Under the program, the company will repurchase up to 530,000 shares, representing 1.5% of its total shares outstanding (excluding treasury shares), for a total of ¥2,000 million. The repurchase program is valid till December 18, 2026. As of February 28, 2026, the company had 35,449,727 shares outstanding (excluding treasury shares) and had 940,273 shares in treasury.最新情報をもっと見るRecent updatesお知らせ • Jun 03Mochida Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 03, 2026Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 03, 2026Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥223 (vs JP¥160 in FY 2025)Full year 2026 results: EPS: JP¥223 (up from JP¥160 in FY 2025). Revenue: JP¥117.0b (up 11% from FY 2025). Net income: JP¥7.90b (up 39% from FY 2025). Profit margin: 6.8% (up from 5.4% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.Board Change • May 20Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Outside Director Sanae Tanaka was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.お知らせ • May 15Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026.お知らせ • May 09Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026お知らせ • Mar 30Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces an Equity Buyback for 530,000 shares, representing 1.5% for ¥2,000 million.Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces a share repurchase program. Under the program, the company will repurchase up to 530,000 shares, representing 1.5% of its total shares outstanding (excluding treasury shares), for a total of ¥2,000 million. The repurchase program is valid till December 18, 2026. As of February 28, 2026, the company had 35,449,727 shares outstanding (excluding treasury shares) and had 940,273 shares in treasury.お知らせ • Nov 29Mochida Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026お知らせ • Sep 23Mochida Pharmaceutical Co., Ltd. (TSE:4534) agreed to acquire 20% stake in And Pharma Co., Ltd. from Godo Kaisha JEH for ¥16.2 billion.Mochida Pharmaceutical Co., Ltd. (TSE:4534) agreed to acquire 20% stake in And Pharma Co., Ltd. from Godo Kaisha JEH for ¥16.2 billion on September 19, 2025. On September 22, 2025, an agreement was signed by the parties. A cash consideration of ¥16.2 billion will be paid by Mochida Pharmaceutical Co., Ltd. In a related transaction, ITOCHU Corporation also agreed to acquire 20% stake in And Pharma Co., Ltd. from Godo Kaisha JEH. The expected completion of the transaction is October 1, 2025.お知らせ • Sep 02Mochida Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 04, 2025Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 04, 2025お知らせ • Jun 27Mochida Pharmaceutical Co., Ltd. Approves Changes to the Special Committee MembersMochida Pharmaceutical Co., Ltd. at its AGM held on June 27, 2025 approved changes of the Special Committee members under the Policy. Special Committee members after the changes as follows: Shigeaki Yoshikawa, Born in 1962; Career Summary: Apr. 1989 Registered as an Attorney-At-Law (To the Present); Sep. 1991 Representative At Sanae Tanaka Law Office (To the Present); Mar. 2011 Outside Director At Noevir Holdings Co., Ltd.; Mar. 2015 Outside Director At Pilot Corporation May. 2015 Outside Director At Shochiku Co., Ltd. Mar. 2023; Outside Audit & Supervisory Board Member At Asahi Group Holdings, Ltd. (Outside Director Since March 2025) (To the Present) June 2023; Outside Director At Tv Asahi Holdings Corporation (To the Present); June 2025 Outside Director of the Company (To the Present). Yoshifumi Miyata; Born in 1952. Career Summary: Apr. 1978 Joined the Dai-Ichi Mutual Life Insurance Company; Apr. 2006 Executive Officer and General Manager of Financial Institution Relations Department At the Dai-Ichi Mutual Life Insurance Company; Apr. 2009 Managing Executive Officer of the Dai-Ichi Mutual Life Insurance Company Jun. 2010 Outside Audit & Supervisory Board Member of Tsugami Corporation; Jun. 2012 Representative Director and Vice-President of Trust & Custody Services Bank, Ltd.; Oct. 2018 Outside Director At Wellnest Communications Inc. (To the Present); Jun. 2021 Outside Audit & Supervisory Board Member of the Company (To the Present). Sanae Tanaka; Born in 1962. Career Summary: Apr. 1989 Registered as an Attorney-At-Law (To the Present); Sep. 1991 Representative At Sanae Tanaka Law Office (To the Present); Mar. 2011 Outside Director At Noevir Holdings Co., Ltd; Mar. 2015 Outside Director At Pilot Corporation; May. 2015 Outside Director At Shochiku Co., Ltd.; Mar. 2023 Outside Audit & Supervisory Board Member At Asahi Group Holdings, Ltd. (Outside Director Since March 2025) (To the Present); Jun. 2023 Outside Director At Tv Asahi Holdings Corporation (To the Present) Jun. 2025 Outside Director of the Company (To the Present).お知らせ • Jun 04Mochida Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 01, 2025Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 01, 2025お知らせ • May 12+ 2 more updatesMochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.お知らせ • Mar 04Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025お知らせ • Nov 30Mochida Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 07, 2025Reported Earnings • Nov 03Second quarter 2025 earnings released: EPS: JP¥35.85 (vs JP¥32.03 in 2Q 2024)Second quarter 2025 results: EPS: JP¥35.85 (up from JP¥32.03 in 2Q 2024). Revenue: JP¥25.7b (up 3.9% from 2Q 2024). Net income: JP¥1.27b (up 11% from 2Q 2024). Profit margin: 4.9% (up from 4.7% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Sep 20Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 02 December 2024. Payout ratio is a comfortable 65% but the company is not cash flow positive. Trailing yield: 2.5%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.1%).New Risk • Sep 17New major risk - Revenue and earnings growthEarnings have declined by 0.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.7% per year over the past 5 years. Minor Risk Paying a dividend despite having no free cash flows.Buy Or Sell Opportunity • Aug 29Now 21% undervaluedOver the last 90 days, the stock has risen 16% to €20.00. The fair value is estimated to be €25.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 27%. Revenue is forecast to grow by 4.8% in 2 years. Earnings are forecast to grow by 55% in the next 2 years.お知らせ • Aug 27Mochida Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 01, 2024Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 01, 2024Reported Earnings • Aug 05First quarter 2025 earnings released: EPS: JP¥43.84 (vs JP¥46.23 in 1Q 2024)First quarter 2025 results: EPS: JP¥43.84 (down from JP¥46.23 in 1Q 2024). Revenue: JP¥25.4b (up 2.7% from 1Q 2024). Net income: JP¥1.55b (down 7.9% from 1Q 2024). Profit margin: 6.1% (down from 6.8% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Buy Or Sell Opportunity • Aug 02Now 22% undervaluedOver the last 90 days, the stock has risen 2.6% to €19.50. The fair value is estimated to be €25.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 22%. For the next 3 years, revenue is forecast to grow by 2.2% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.Declared Dividend • Jul 11Final dividend of JP¥40.00 announcedShareholders will receive a dividend of JP¥40.00. Ex-date: 27th September 2024 Payment date: 2nd December 2024 Dividend yield will be 219%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is not covered by earnings (144% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 60% to bring the payout ratio under control. EPS is expected to grow by 54% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.お知らせ • Jun 06Mochida Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 02, 2024Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 02, 2024Reported Earnings • May 16Full year 2024 earnings released: EPS: JP¥127 (vs JP¥179 in FY 2023)Full year 2024 results: EPS: JP¥127 (down from JP¥179 in FY 2023). Revenue: JP¥102.9b (flat on FY 2023). Net income: JP¥4.55b (down 32% from FY 2023). Profit margin: 4.4% (down from 6.4% in FY 2023). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • May 15Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024.Upcoming Dividend • Mar 21Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is on the higher end at 96% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.9%). In line with average of industry peers (2.4%).お知らせ • Mar 02Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 13, 2024Reported Earnings • Feb 06Third quarter 2024 earnings released: EPS: JP¥45.16 (vs JP¥112 in 3Q 2023)Third quarter 2024 results: EPS: JP¥45.16 (down from JP¥112 in 3Q 2023). Revenue: JP¥28.7b (up 1.9% from 3Q 2023). Net income: JP¥1.61b (down 61% from 3Q 2023). Profit margin: 5.6% (down from 15% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 15% per year.お知らせ • Feb 05+ 1 more updateMochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024Mochida Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects net sales to be JPY 102,000 million. Operating income to be JPY 5,500 million. Profit attributable to owners of parent to be JPY 4,400 million. Basic earnings per share to be JPY 123.85.お知らせ • Dec 02Mochida Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 05, 2024Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 05, 2024Reported Earnings • Nov 04Second quarter 2024 earnings released: EPS: JP¥32.02 (vs JP¥20.52 in 2Q 2023)Second quarter 2024 results: EPS: JP¥32.02 (up from JP¥20.52 in 2Q 2023). Revenue: JP¥24.7b (down 3.1% from 2Q 2023). Net income: JP¥1.15b (up 50% from 2Q 2023). Profit margin: 4.7% (up from 3.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.Upcoming Dividend • Sep 21Upcoming dividend of JP¥40.00 per share at 2.4% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 01 December 2023. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (2.5%).お知らせ • Aug 30Mochida Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 02, 2023Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 02, 2023Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: JP¥46.23 (vs JP¥83.98 in 1Q 2023)First quarter 2024 results: EPS: JP¥46.23 (down from JP¥83.98 in 1Q 2023). Revenue: JP¥24.7b (down 11% from 1Q 2023). Net income: JP¥1.69b (down 47% from 1Q 2023). Profit margin: 6.8% (down from 11% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.お知らせ • May 31Mochida Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023Reported Earnings • May 17Full year 2023 earnings released: EPS: JP¥179 (vs JP¥277 in FY 2022)Full year 2023 results: EPS: JP¥179 (down from JP¥277 in FY 2022). Revenue: JP¥103.3b (down 6.3% from FY 2022). Net income: JP¥6.65b (down 37% from FY 2022). Profit margin: 6.4% (down from 9.6% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • May 16+ 1 more updateMochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023.Upcoming Dividend • Mar 23Upcoming dividend of JP¥40.00 per share at 2.4% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.8%).Reported Earnings • Feb 09Third quarter 2023 earnings released: EPS: JP¥112 (vs JP¥138 in 3Q 2022)Third quarter 2023 results: EPS: JP¥112 (down from JP¥138 in 3Q 2022). Revenue: JP¥28.2b (down 8.5% from 3Q 2022). Net income: JP¥4.16b (down 21% from 3Q 2022). Profit margin: 15% (down from 17% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Nov 27Mochida Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 06, 2023Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 06, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥20.52 (vs JP¥59.14 in 2Q 2022)Second quarter 2023 results: EPS: JP¥20.52 (down from JP¥59.14 in 2Q 2022). Revenue: JP¥25.5b (down 4.3% from 2Q 2022). Net income: JP¥768.0m (down 66% from 2Q 2022). Profit margin: 3.0% (down from 8.5% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Tomoaki Sonoda was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 06Second quarter 2023 earnings released: EPS: JP¥20.52 (vs JP¥59.14 in 2Q 2022)Second quarter 2023 results: EPS: JP¥20.52 (down from JP¥59.14 in 2Q 2022). Revenue: JP¥25.5b (down 4.3% from 2Q 2022). Net income: JP¥768.0m (down 66% from 2Q 2022). Profit margin: 3.0% (down from 8.5% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 01 December 2022. Payout ratio is a comfortable 31% and the cash payout ratio is 77%. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (2.9%).お知らせ • Aug 27Mochida Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 04, 2022Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2023 results on Nov 04, 2022Reported Earnings • Aug 02First quarter 2023 earnings released: EPS: JP¥83.98 (vs JP¥69.33 in 1Q 2022)First quarter 2023 results: EPS: JP¥83.98 (up from JP¥69.33 in 1Q 2022). Revenue: JP¥27.7b (up 1.2% from 1Q 2022). Net income: JP¥3.16b (up 19% from 1Q 2022). Profit margin: 11% (up from 9.7% in 1Q 2022). Over the next year, revenue is forecast to stay flat compared to a 8.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Aug 02Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces an Equity Buyback for 1,190,000 shares, representing 3.17% for ¥3,500 million.Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces a share repurchase program. Under the program, the company will repurchase up to 1,190,000 shares, representing 3.17% of its total shares outstanding (excluding treasury shares), for a total of ¥3,500 million. The purpose of repurchase program is to flexibly invest capital in response to changes in the business environment, in addition to enhancing shareholder returns and improving capital efficiency. The repurchase program is valid till March 24, 2023. As of July 31, 2022, the company had 37,569,339 shares outstanding (excluding treasury shares) and had 2,590,661 shares in treasury.お知らせ • May 29Mochida Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Aug 01, 2022Reported Earnings • May 16Full year 2022 earnings released: EPS: JP¥277 (vs JP¥222 in FY 2021)Full year 2022 results: EPS: JP¥277 (up from JP¥222 in FY 2021). Revenue: JP¥110.2b (up 7.0% from FY 2021). Net income: JP¥10.6b (up 23% from FY 2021). Profit margin: 9.6% (up from 8.3% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to stay flat compared to a 6.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • May 15Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. 2 independent directors (8 non-independent directors). Outside Director Nana Otsuki was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 08Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results on May 13, 2022Upcoming Dividend • Mar 23Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 30 June 2022. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (2.6%).Reported Earnings • Feb 06Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: JP¥138 (up from JP¥77.56 in 3Q 2021). Revenue: JP¥30.8b (up 9.0% from 3Q 2021). Net income: JP¥5.26b (up 76% from 3Q 2021). Profit margin: 17% (up from 11% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.7%. Over the next year, revenue is forecast to stay flat compared to a 7.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 06Second quarter 2022 earnings released: EPS JP¥59.13 (vs JP¥52.74 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥26.6b (up 9.9% from 2Q 2021). Net income: JP¥2.26b (up 11% from 2Q 2021). Profit margin: 8.5% (up from 8.4% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 01 December 2021. Trailing yield: 2.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.7%).Reported Earnings • Aug 03First quarter 2022 earnings released: EPS JP¥69.33 (vs JP¥86.88 in 1Q 2021)The company reported a poor first quarter result with weaker earnings and profit margins, although revenues were flat. First quarter 2022 results: Revenue: JP¥27.4b (flat on 1Q 2021). Net income: JP¥2.65b (down 21% from 1Q 2021). Profit margin: 9.7% (down from 12% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Reported Earnings • May 17Full year 2021 earnings released: EPS JP¥222 (vs JP¥118 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥103.0b (up 1.2% from FY 2020). Net income: JP¥8.59b (up 87% from FY 2020). Profit margin: 8.3% (up from 4.5% in FY 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Mar 24Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 29 June 2021. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (3.0%).Is New 90 Day High Low • Feb 16New 90-day high: €33.80The company is up 2.0% from its price of €33.00 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.Reported Earnings • Feb 07Third quarter 2021 earnings released: EPS JP¥77.56 (vs JP¥45.66 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥28.3b (up 2.4% from 3Q 2020). Net income: JP¥3.00b (up 68% from 3Q 2020). Profit margin: 11% (up from 6.5% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Feb 07Revenue beats expectationsRevenue exceeded analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 1.4%, compared to a 2.3% growth forecast for the Pharmaceuticals industry in Germany.お知らせ • Jan 12Mochida Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 05, 2021Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2021 results on Feb 05, 2021Is New 90 Day High Low • Dec 24New 90-day low: €29.80The company is down 9.0% from its price of €32.80 on 25 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.Analyst Estimate Surprise Post Earnings • Nov 15Revenue misses expectationsRevenue missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 1.6%, compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.Reported Earnings • Nov 15Second quarter 2021 earnings released: EPS JP¥52.74The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: JP¥24.2b (down 3.1% from 2Q 2020). Net income: JP¥2.04b (up 59% from 2Q 2020). Profit margin: 8.4% (up from 5.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Nov 05Revenue misses expectationsRevenue missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 3.0%, compared to a 2.6% growth forecast for the Pharmaceuticals industry in Germany.Reported Earnings • Nov 05Second quarter 2021 earnings released: EPS JP¥52.74The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: JP¥24.2b (down 3.1% from 2Q 2020). Net income: JP¥2.04b (up 59% from 2Q 2020). Profit margin: 8.4% (up from 5.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Sep 28New 90-day high: €34.80The company is up 7.0% from its price of €32.60 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.株主還元MFYDE PharmaceuticalsDE 市場7D-1.2%-2.0%0.1%1Y-5.8%36.5%-0.5%株主還元を見る業界別リターン: MFY過去 1 年間で36.5 % の収益を上げたGerman Pharmaceuticals業界を下回りました。リターン対市場: MFYは、過去 1 年間で-0.5 % のリターンを上げたGerman市場を下回りました。価格変動Is MFY's price volatile compared to industry and market?MFY volatilityMFY Average Weekly Movement4.0%Pharmaceuticals Industry Average Movement6.2%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%安定した株価: MFY 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: MFYの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19131,479Naoyuki Mochidawww.mochida.co.jp持田製薬株式会社は日本で医薬品とヘルスケア製品を製造・販売している。同社は循環器、産科、婦人科、皮膚科、精神科、消化器科の治療用医薬品を提供している。潰瘍性大腸炎治療薬「リアルダ」、慢性便秘症治療薬「グーフィス」「モビコール」、抗うつ薬「レクサプロ」、高脂血症・閉塞性動脈硬化症治療薬「エパデール」、痛風・高尿酸血症治療薬「ウルセ」、肺動脈性肺高血圧症治療薬「トレプロスト」などを提供している。また、長時間作用型カルシウム拮抗降圧剤「アテレック」、慢性疼痛・抜歯後疼痛用鎮痛剤「トラムセット」、抗凝固剤「ヘパリンナトリウム持田製薬」、尖圭コンジローマ・光線性角化症治療剤「ベセルナ」、子宮内膜症・子宮腺筋症・月経困難症治療剤「ディナゲスト」を提供している。さらに、スキンケア、ベビーケア、パーソナルケア、介護用品も提供している。また、潰瘍性大腸炎、高トリグリセリド血症、不眠症、痛風・高尿酸血症、間質性肺疾患に伴う肺高血圧症の治療薬としてメサラジン、イコサペント酸エチル、ダリドレキサント、ドチヌラド、トレプロスチニルを、関節軟骨病変の治療薬としてdMD-001、海綿体神経損傷の治療薬としてdMD-002を開発している。持田製薬株式会社は1913年に設立され、東京に本社を置いています。もっと見るMochida Pharmaceutical Co., Ltd. 基礎のまとめMochida Pharmaceutical の収益と売上を時価総額と比較するとどうか。MFY 基礎統計学時価総額€592.88m収益（TTM）€42.40m売上高(TTM)€627.42m14.0xPER（株価収益率0.9xP/SレシオMFY は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計MFY 損益計算書（TTM）収益JP¥116.95b売上原価JP¥60.69b売上総利益JP¥56.26bその他の費用JP¥48.36b収益JP¥7.90b直近の収益報告Mar 31, 2026次回決算日Aug 03, 2026一株当たり利益（EPS）223.12グロス・マージン48.11%純利益率6.76%有利子負債／自己資本比率7.1%MFY の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.7%現在の配当利回り36%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 00:29終値2026/07/23 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mochida Pharmaceutical Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Taku OuchiSMBC NIKKO
お知らせ • Jun 03Mochida Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 03, 2026Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 03, 2026
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥223 (vs JP¥160 in FY 2025)Full year 2026 results: EPS: JP¥223 (up from JP¥160 in FY 2025). Revenue: JP¥117.0b (up 11% from FY 2025). Net income: JP¥7.90b (up 39% from FY 2025). Profit margin: 6.8% (up from 5.4% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Board Change • May 20Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Outside Director Sanae Tanaka was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • May 15Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026.
お知らせ • May 09Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026
お知らせ • Mar 30Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces an Equity Buyback for 530,000 shares, representing 1.5% for ¥2,000 million.Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces a share repurchase program. Under the program, the company will repurchase up to 530,000 shares, representing 1.5% of its total shares outstanding (excluding treasury shares), for a total of ¥2,000 million. The repurchase program is valid till December 18, 2026. As of February 28, 2026, the company had 35,449,727 shares outstanding (excluding treasury shares) and had 940,273 shares in treasury.
お知らせ • Jun 03Mochida Pharmaceutical Co., Ltd. to Report Q1, 2027 Results on Aug 03, 2026Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2027 results on Aug 03, 2026
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥223 (vs JP¥160 in FY 2025)Full year 2026 results: EPS: JP¥223 (up from JP¥160 in FY 2025). Revenue: JP¥117.0b (up 11% from FY 2025). Net income: JP¥7.90b (up 39% from FY 2025). Profit margin: 6.8% (up from 5.4% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings.
Board Change • May 20Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Outside Director Sanae Tanaka was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
お知らせ • May 15Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 25, 2026.
お知らせ • May 09Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2026 Results on May 15, 2026Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2026 results on May 15, 2026
お知らせ • Mar 30Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces an Equity Buyback for 530,000 shares, representing 1.5% for ¥2,000 million.Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces a share repurchase program. Under the program, the company will repurchase up to 530,000 shares, representing 1.5% of its total shares outstanding (excluding treasury shares), for a total of ¥2,000 million. The repurchase program is valid till December 18, 2026. As of February 28, 2026, the company had 35,449,727 shares outstanding (excluding treasury shares) and had 940,273 shares in treasury.
お知らせ • Nov 29Mochida Pharmaceutical Co., Ltd. to Report Q3, 2026 Results on Feb 06, 2026Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2026 results on Feb 06, 2026
お知らせ • Sep 23Mochida Pharmaceutical Co., Ltd. (TSE:4534) agreed to acquire 20% stake in And Pharma Co., Ltd. from Godo Kaisha JEH for ¥16.2 billion.Mochida Pharmaceutical Co., Ltd. (TSE:4534) agreed to acquire 20% stake in And Pharma Co., Ltd. from Godo Kaisha JEH for ¥16.2 billion on September 19, 2025. On September 22, 2025, an agreement was signed by the parties. A cash consideration of ¥16.2 billion will be paid by Mochida Pharmaceutical Co., Ltd. In a related transaction, ITOCHU Corporation also agreed to acquire 20% stake in And Pharma Co., Ltd. from Godo Kaisha JEH. The expected completion of the transaction is October 1, 2025.
お知らせ • Sep 02Mochida Pharmaceutical Co., Ltd. to Report Q2, 2026 Results on Nov 04, 2025Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2026 results on Nov 04, 2025
お知らせ • Jun 27Mochida Pharmaceutical Co., Ltd. Approves Changes to the Special Committee MembersMochida Pharmaceutical Co., Ltd. at its AGM held on June 27, 2025 approved changes of the Special Committee members under the Policy. Special Committee members after the changes as follows: Shigeaki Yoshikawa, Born in 1962; Career Summary: Apr. 1989 Registered as an Attorney-At-Law (To the Present); Sep. 1991 Representative At Sanae Tanaka Law Office (To the Present); Mar. 2011 Outside Director At Noevir Holdings Co., Ltd.; Mar. 2015 Outside Director At Pilot Corporation May. 2015 Outside Director At Shochiku Co., Ltd. Mar. 2023; Outside Audit & Supervisory Board Member At Asahi Group Holdings, Ltd. (Outside Director Since March 2025) (To the Present) June 2023; Outside Director At Tv Asahi Holdings Corporation (To the Present); June 2025 Outside Director of the Company (To the Present). Yoshifumi Miyata; Born in 1952. Career Summary: Apr. 1978 Joined the Dai-Ichi Mutual Life Insurance Company; Apr. 2006 Executive Officer and General Manager of Financial Institution Relations Department At the Dai-Ichi Mutual Life Insurance Company; Apr. 2009 Managing Executive Officer of the Dai-Ichi Mutual Life Insurance Company Jun. 2010 Outside Audit & Supervisory Board Member of Tsugami Corporation; Jun. 2012 Representative Director and Vice-President of Trust & Custody Services Bank, Ltd.; Oct. 2018 Outside Director At Wellnest Communications Inc. (To the Present); Jun. 2021 Outside Audit & Supervisory Board Member of the Company (To the Present). Sanae Tanaka; Born in 1962. Career Summary: Apr. 1989 Registered as an Attorney-At-Law (To the Present); Sep. 1991 Representative At Sanae Tanaka Law Office (To the Present); Mar. 2011 Outside Director At Noevir Holdings Co., Ltd; Mar. 2015 Outside Director At Pilot Corporation; May. 2015 Outside Director At Shochiku Co., Ltd.; Mar. 2023 Outside Audit & Supervisory Board Member At Asahi Group Holdings, Ltd. (Outside Director Since March 2025) (To the Present); Jun. 2023 Outside Director At Tv Asahi Holdings Corporation (To the Present) Jun. 2025 Outside Director of the Company (To the Present).
お知らせ • Jun 04Mochida Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Aug 01, 2025Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Aug 01, 2025
お知らせ • May 12+ 2 more updatesMochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2025.
お知らせ • Mar 04Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on May 12, 2025Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on May 12, 2025
お知らせ • Nov 30Mochida Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Feb 07, 2025
Reported Earnings • Nov 03Second quarter 2025 earnings released: EPS: JP¥35.85 (vs JP¥32.03 in 2Q 2024)Second quarter 2025 results: EPS: JP¥35.85 (up from JP¥32.03 in 2Q 2024). Revenue: JP¥25.7b (up 3.9% from 2Q 2024). Net income: JP¥1.27b (up 11% from 2Q 2024). Profit margin: 4.9% (up from 4.7% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Sep 20Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 02 December 2024. Payout ratio is a comfortable 65% but the company is not cash flow positive. Trailing yield: 2.5%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (1.1%).
New Risk • Sep 17New major risk - Revenue and earnings growthEarnings have declined by 0.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.7% per year over the past 5 years. Minor Risk Paying a dividend despite having no free cash flows.
Buy Or Sell Opportunity • Aug 29Now 21% undervaluedOver the last 90 days, the stock has risen 16% to €20.00. The fair value is estimated to be €25.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 27%. Revenue is forecast to grow by 4.8% in 2 years. Earnings are forecast to grow by 55% in the next 2 years.
お知らせ • Aug 27Mochida Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Nov 01, 2024Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2025 results on Nov 01, 2024
Reported Earnings • Aug 05First quarter 2025 earnings released: EPS: JP¥43.84 (vs JP¥46.23 in 1Q 2024)First quarter 2025 results: EPS: JP¥43.84 (down from JP¥46.23 in 1Q 2024). Revenue: JP¥25.4b (up 2.7% from 1Q 2024). Net income: JP¥1.55b (down 7.9% from 1Q 2024). Profit margin: 6.1% (down from 6.8% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Buy Or Sell Opportunity • Aug 02Now 22% undervaluedOver the last 90 days, the stock has risen 2.6% to €19.50. The fair value is estimated to be €25.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 22%. For the next 3 years, revenue is forecast to grow by 2.2% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.
Declared Dividend • Jul 11Final dividend of JP¥40.00 announcedShareholders will receive a dividend of JP¥40.00. Ex-date: 27th September 2024 Payment date: 2nd December 2024 Dividend yield will be 219%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is not covered by earnings (144% earnings payout ratio) and the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 60% to bring the payout ratio under control. EPS is expected to grow by 54% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.
お知らせ • Jun 06Mochida Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Aug 02, 2024Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Aug 02, 2024
Reported Earnings • May 16Full year 2024 earnings released: EPS: JP¥127 (vs JP¥179 in FY 2023)Full year 2024 results: EPS: JP¥127 (down from JP¥179 in FY 2023). Revenue: JP¥102.9b (flat on FY 2023). Net income: JP¥4.55b (down 32% from FY 2023). Profit margin: 4.4% (down from 6.4% in FY 2023). Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • May 15Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 27, 2024.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 01 July 2024. Payout ratio is on the higher end at 96% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.9%). In line with average of industry peers (2.4%).
お知らせ • Mar 02Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 13, 2024Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on May 13, 2024
Reported Earnings • Feb 06Third quarter 2024 earnings released: EPS: JP¥45.16 (vs JP¥112 in 3Q 2023)Third quarter 2024 results: EPS: JP¥45.16 (down from JP¥112 in 3Q 2023). Revenue: JP¥28.7b (up 1.9% from 3Q 2023). Net income: JP¥1.61b (down 61% from 3Q 2023). Profit margin: 5.6% (down from 15% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 15% per year.
お知らせ • Feb 05+ 1 more updateMochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024Mochida Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the fiscal year ending March 31, 2024. For the year, the company expects net sales to be JPY 102,000 million. Operating income to be JPY 5,500 million. Profit attributable to owners of parent to be JPY 4,400 million. Basic earnings per share to be JPY 123.85.
お知らせ • Dec 02Mochida Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Feb 05, 2024Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Feb 05, 2024
Reported Earnings • Nov 04Second quarter 2024 earnings released: EPS: JP¥32.02 (vs JP¥20.52 in 2Q 2023)Second quarter 2024 results: EPS: JP¥32.02 (up from JP¥20.52 in 2Q 2023). Revenue: JP¥24.7b (down 3.1% from 2Q 2023). Net income: JP¥1.15b (up 50% from 2Q 2023). Profit margin: 4.7% (up from 3.0% in 2Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings.
Upcoming Dividend • Sep 21Upcoming dividend of JP¥40.00 per share at 2.4% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 01 December 2023. Payout ratio is a comfortable 57% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.8%). In line with average of industry peers (2.5%).
お知らせ • Aug 30Mochida Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 02, 2023Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2024 results on Nov 02, 2023
Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: JP¥46.23 (vs JP¥83.98 in 1Q 2023)First quarter 2024 results: EPS: JP¥46.23 (down from JP¥83.98 in 1Q 2023). Revenue: JP¥24.7b (down 11% from 1Q 2023). Net income: JP¥1.69b (down 47% from 1Q 2023). Profit margin: 6.8% (down from 11% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.8% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
お知らせ • May 31Mochida Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Aug 04, 2023Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Aug 04, 2023
Reported Earnings • May 17Full year 2023 earnings released: EPS: JP¥179 (vs JP¥277 in FY 2022)Full year 2023 results: EPS: JP¥179 (down from JP¥277 in FY 2022). Revenue: JP¥103.3b (down 6.3% from FY 2022). Net income: JP¥6.65b (down 37% from FY 2022). Profit margin: 6.4% (down from 9.6% in FY 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • May 16+ 1 more updateMochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥40.00 per share at 2.4% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 30 June 2023. Payout ratio is a comfortable 22% and this is well supported by cash flows. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.8%).
Reported Earnings • Feb 09Third quarter 2023 earnings released: EPS: JP¥112 (vs JP¥138 in 3Q 2022)Third quarter 2023 results: EPS: JP¥112 (down from JP¥138 in 3Q 2022). Revenue: JP¥28.2b (down 8.5% from 3Q 2022). Net income: JP¥4.16b (down 21% from 3Q 2022). Profit margin: 15% (down from 17% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Nov 27Mochida Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Feb 06, 2023Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Feb 06, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: EPS: JP¥20.52 (vs JP¥59.14 in 2Q 2022)Second quarter 2023 results: EPS: JP¥20.52 (down from JP¥59.14 in 2Q 2022). Revenue: JP¥25.5b (down 4.3% from 2Q 2022). Net income: JP¥768.0m (down 66% from 2Q 2022). Profit margin: 3.0% (down from 8.5% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 7 non-independent directors. Independent Outside Director Tomoaki Sonoda was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 06Second quarter 2023 earnings released: EPS: JP¥20.52 (vs JP¥59.14 in 2Q 2022)Second quarter 2023 results: EPS: JP¥20.52 (down from JP¥59.14 in 2Q 2022). Revenue: JP¥25.5b (down 4.3% from 2Q 2022). Net income: JP¥768.0m (down 66% from 2Q 2022). Profit margin: 3.0% (down from 8.5% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 01 December 2022. Payout ratio is a comfortable 31% and the cash payout ratio is 77%. Trailing yield: 2.4%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (2.9%).
お知らせ • Aug 27Mochida Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Nov 04, 2022Mochida Pharmaceutical Co., Ltd. announced that they will report Q2, 2023 results on Nov 04, 2022
Reported Earnings • Aug 02First quarter 2023 earnings released: EPS: JP¥83.98 (vs JP¥69.33 in 1Q 2022)First quarter 2023 results: EPS: JP¥83.98 (up from JP¥69.33 in 1Q 2022). Revenue: JP¥27.7b (up 1.2% from 1Q 2022). Net income: JP¥3.16b (up 19% from 1Q 2022). Profit margin: 11% (up from 9.7% in 1Q 2022). Over the next year, revenue is forecast to stay flat compared to a 8.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Aug 02Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces an Equity Buyback for 1,190,000 shares, representing 3.17% for ¥3,500 million.Mochida Pharmaceutical Co., Ltd. (TSE:4534) announces a share repurchase program. Under the program, the company will repurchase up to 1,190,000 shares, representing 3.17% of its total shares outstanding (excluding treasury shares), for a total of ¥3,500 million. The purpose of repurchase program is to flexibly invest capital in response to changes in the business environment, in addition to enhancing shareholder returns and improving capital efficiency. The repurchase program is valid till March 24, 2023. As of July 31, 2022, the company had 37,569,339 shares outstanding (excluding treasury shares) and had 2,590,661 shares in treasury.
お知らせ • May 29Mochida Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022Mochida Pharmaceutical Co., Ltd. announced that they will report Q1, 2023 results on Aug 01, 2022
Reported Earnings • May 16Full year 2022 earnings released: EPS: JP¥277 (vs JP¥222 in FY 2021)Full year 2022 results: EPS: JP¥277 (up from JP¥222 in FY 2021). Revenue: JP¥110.2b (up 7.0% from FY 2021). Net income: JP¥10.6b (up 23% from FY 2021). Profit margin: 9.6% (up from 8.3% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to stay flat compared to a 6.2% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • May 15Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022Mochida Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2022.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 11 experienced directors. No highly experienced directors. 2 independent directors (8 non-independent directors). Outside Director Nana Otsuki was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 08Mochida Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022Mochida Pharmaceutical Co., Ltd. announced that they will report fiscal year 2022 results on May 13, 2022
Upcoming Dividend • Mar 23Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 30 June 2022. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (2.6%).
Reported Earnings • Feb 06Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: JP¥138 (up from JP¥77.56 in 3Q 2021). Revenue: JP¥30.8b (up 9.0% from 3Q 2021). Net income: JP¥5.26b (up 76% from 3Q 2021). Profit margin: 17% (up from 11% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 7.7%. Over the next year, revenue is forecast to stay flat compared to a 7.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 06Second quarter 2022 earnings released: EPS JP¥59.13 (vs JP¥52.74 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥26.6b (up 9.9% from 2Q 2021). Net income: JP¥2.26b (up 11% from 2Q 2021). Profit margin: 8.5% (up from 8.4% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 01 December 2021. Trailing yield: 2.3%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (2.7%).
Reported Earnings • Aug 03First quarter 2022 earnings released: EPS JP¥69.33 (vs JP¥86.88 in 1Q 2021)The company reported a poor first quarter result with weaker earnings and profit margins, although revenues were flat. First quarter 2022 results: Revenue: JP¥27.4b (flat on 1Q 2021). Net income: JP¥2.65b (down 21% from 1Q 2021). Profit margin: 9.7% (down from 12% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 17Full year 2021 earnings released: EPS JP¥222 (vs JP¥118 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: JP¥103.0b (up 1.2% from FY 2020). Net income: JP¥8.59b (up 87% from FY 2020). Profit margin: 8.3% (up from 4.5% in FY 2020). The increase in margin was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Mar 24Upcoming dividend of JP¥40.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 29 June 2021. Trailing yield: 1.7%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (3.0%).
Is New 90 Day High Low • Feb 16New 90-day high: €33.80The company is up 2.0% from its price of €33.00 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 14% over the same period.
Reported Earnings • Feb 07Third quarter 2021 earnings released: EPS JP¥77.56 (vs JP¥45.66 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥28.3b (up 2.4% from 3Q 2020). Net income: JP¥3.00b (up 68% from 3Q 2020). Profit margin: 11% (up from 6.5% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Feb 07Revenue beats expectationsRevenue exceeded analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 1.4%, compared to a 2.3% growth forecast for the Pharmaceuticals industry in Germany.
お知らせ • Jan 12Mochida Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 05, 2021Mochida Pharmaceutical Co., Ltd. announced that they will report Q3, 2021 results on Feb 05, 2021
Is New 90 Day High Low • Dec 24New 90-day low: €29.80The company is down 9.0% from its price of €32.80 on 25 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period.
Analyst Estimate Surprise Post Earnings • Nov 15Revenue misses expectationsRevenue missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 1.6%, compared to a 2.8% growth forecast for the Pharmaceuticals industry in Germany.
Reported Earnings • Nov 15Second quarter 2021 earnings released: EPS JP¥52.74The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: JP¥24.2b (down 3.1% from 2Q 2020). Net income: JP¥2.04b (up 59% from 2Q 2020). Profit margin: 8.4% (up from 5.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Nov 05Revenue misses expectationsRevenue missed analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 3.0%, compared to a 2.6% growth forecast for the Pharmaceuticals industry in Germany.
Reported Earnings • Nov 05Second quarter 2021 earnings released: EPS JP¥52.74The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: JP¥24.2b (down 3.1% from 2Q 2020). Net income: JP¥2.04b (up 59% from 2Q 2020). Profit margin: 8.4% (up from 5.1% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Sep 28New 90-day high: €34.80The company is up 7.0% from its price of €32.60 on 30 June 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
